Site Search
Professionals 648 results
Capabilities 91 results
Region
Winston’s deep experience representing companies and investors across Latin America and the Caribbean has made the firm a “go-to” resource for the strategic development of our clients’ businesses and the vigorous protection of their interests in the region. With broad command of a diverse range of issues within the region’s key industry sectors, we advise Fortune 500 companies, government and quasi-governmental entities, financial institutions, private equity and other investors, domestic and international oil and gas exploration and production companies, refiners and shippers, and a range of commercial and infrastructure developers.
Industry
Insurance plays an essential role in risk mitigation for financial services companies. As risks evolve, questions often arise concerning the scope of insurance coverage and the interpretation and application of policy provisions. Winston’s insurance lawyers provide companies with best-in-class advice, corporate and transactional counsel, and, if need be, litigation defense in high-stakes coverage disputes and class actions. We have achieved excellent outcomes for our clients in matters involving a wide variety of insurance policies and claims, including cybersecurity, travel, long-term care, and annuities, among others. Moreover, we have experience in emerging issues and industries, such as blockchain technology and artificial intelligence, both of which present insurers with a unique and complicated set of risks and opportunities.
Industry
Winston is well regarded for deep and broad experience advising clients in the development, construction, financing and refinancing, acquisition, and operation of major infrastructure assets, including several award-winning deals and public-private-partnership (PPPs or P3s) projects in North America, Latin America, and Europe. Recognized for our ability to “take complex issues and boil them down to pragmatic solutions” (Chambers USA 2023), our team represents a diverse mix of participants and stakeholders in a broad range of investments and non-recourse/limited recourse financings, and we have experience working on many of the most complex projects, within aggressive time frames, while employing inventive solutions. Likewise, our lawyers help to identify and quantify roadblocks and risks at an early stage, so that we can help our clients—which include developers and sponsors, a full range of lenders and investors, project owners and operators, governments and their agencies, and other project counterparties—evaluate and, to the extent possible, mitigate or eliminate risk.
Experience 466 results
Experience
|February 4, 2026
A Winston & Strawn deal team led by Partners Justin Levy in New York and Paul Amiss in London advised Aeron Defense, a newly formed defense platform established by Ventus Industrial Partners in partnership with GenNx360 Capital Partners and Admiralty Partners, on its acquisition of defense contracting specialists General Tool Company and Magna Machine Company.
Experience
|February 2, 2026
A Winston & Strawn deal team led by Partners Justin Levy in New York and Paul Amiss in London advised Aeron Defense, a newly formed defense platform established by Ventus Industrial Partners in partnership with GenNx360 Capital Partners and Admiralty Partners, on its acquisition of defense contracting specialists General Tool Company and Magna Machine Company.
Experience
|January 29, 2026
A team led by Justin Levy, Austin Leach, and Ben Popeck served as sell-side advisors to GenNx360 Capital Partners in the sale of its portfolio company, Precision Aviation Group, to VSE Corporation for a total upfront consideration of approximately $2.025 billion in cash and equity. PAG expects to generate approximately $615 million of adjusted revenue for the fiscal year ended December 31, 2025. Together, VSE and PAG will create a more diversified, globally scaled aviation aftermarket platform with broader technical capabilities and an expanded portfolio of proprietary repair and solutions content designed to strengthen customer support, extend asset life, and reduce total cost of ownership.
Insights & News 7,669 results
Webinar
|March 10, 2026
Private Fund Focus on Regulatory Trends, Compliance Practices, & SEC Initiatives
Join Winston & Strawn and the Alternative Investment Management Association (AIMA) for a workshop focused on private fund managers, exploring the regulatory trends and compliance practices in a continuously evolving regulatory environment. Partners Beth Kramer and Scott Naidech, and Five Bells Settlement Corp.’s Chief Legal Officer, Matthew Siano, will discuss current SEC initiatives and compliance practices utilized by private equity funds, hedge funds, and alternative investment fund managers relating to conflicts of interest, fees and expenses, performance marketing, annual review, and SEC areas of focus.
Webinar
|February 24, 2026
Venezuela in Transition: The Evolving Investment Landscape
Recent political developments in Venezuela are significantly impacting the country’s outlook, presenting novel challenges and opportunities for investment in the region.
Recognitions
|February 20, 2026
|1 Min Read
Winston & Strawn associate Ashley Wright was recognized by Corporate Counsel among the Next Generation of Leaders (Law Firm) winners in its 2026 Women, Influence & Power in Law (WIPL) Awards. This category recognizes up-and-coming women lawyers who have demonstrated exceptional skill, dedication, and commitment to advancing equality in both the legal profession and their communities.
Other Results 77 results
Law Glossary
What Statutes and Regulations Govern the Approval and Marketing of Biosimilars?
Congress passed the Biologics Price Competition and Innovation Act of 2009 (BPCIA) in 2010 an amendment of the Public Health Services Act. The BPCIA is codified at 42 U.S.C. § 262.
Law Glossary
What Exclusivity Periods Are Associated with Biosimilars?
An applicant may not submit an aBLA until four years after the reference product is licensed by the FDA. (See BPCIA § 351(k).) Further, any biosimilar licenses “may not be made effective” until 12 years after the reference product was licensed. (See BPCIA § 351(l).)